Teladoc Health Inc
NYSE:TDOC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (8.7), the stock would be worth $8.16 (36% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.4 | $6 |
0%
|
| 3-Year Average | 8.7 | $8.16 |
+36%
|
| 5-Year Average | 5.8 | $5.43 |
-9%
|
| Industry Average | 12.9 | $12.09 |
+101%
|
| Country Average | 14.4 | $13.46 |
+124%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$1.2B
|
/ |
Jan 2026
$200.7m
|
= |
|
|
$1.2B
|
/ |
Dec 2026
$290.3m
|
= |
|
|
$1.2B
|
/ |
Dec 2027
$305.1m
|
= |
|
|
$1.2B
|
/ |
Dec 2028
$319.2m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Teladoc Health Inc
NYSE:TDOC
|
1.1B USD | 6.4 | -5.3 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 21.9 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
27.5B USD | 21.1 | 30.2 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.9B AUD | 77.1 | 62.2 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 10.2 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.1B SEK | -133.5 | 96.4 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
5B USD | 15.4 | 43.2 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 14.8 | 18.7 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
18.6B CNY | -118 | -60.4 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 267.9 | -328 | |
| US |
H
|
Heartflow Inc
NASDAQ:HTFL
|
2.7B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Teladoc Health Inc
Glance View
In the bustling landscape of digital healthcare, Teladoc Health Inc. stands as a pioneering beacon, revolutionizing how medical services are delivered and consumed. Originally founded in 2002 in Dallas, Texas, Teladoc began as a straightforward telemedicine platform offering virtual doctor visits via phone and video calls. Over the years, it has adeptly expanded to provide a comprehensive suite of services, including expert medical opinions, AI-driven health analytics, and management of chronic diseases. Through strategic acquisitions, such as the purchase of Livongo Health, Teladoc broadened its offerings to encompass behavioral health and chronic condition management, thereby creating a holistic ecosystem of care. This integration of services is tailored to meet the diverse health needs of its clients, ranging from individual consumers to large employers and health plans. Teladoc's business model hinges on a subscription-based framework, primarily targeting employers and insurance companies who offer their digital healthcare platform as a valuable benefit to their employees or policyholders. By charging these institutional clients a recurring fee, and also collecting per-visit fees from individuals, Teladoc ensures a steady and reliable revenue stream. With the growing acceptance and demand for telehealth solutions, particularly heightened by global events like the COVID-19 pandemic, Teladoc has seen a significant increase in utilization rates. This surge underscores the company's strategy of continuous innovation and investment in technology that enhances user experience and outcomes, positioning Teladoc as a leader in the future of healthcare delivery.
